The study further subdivided the gastric cancer patients according to different pathological features, revealing that CA125, AFP, and CEA levels in stage III-IV patients were higher than in stage I-II patients, and that poorly differentiated patients exhibited higher CA125, AFP, and CEA levels than moderately to well-differentiated patients. Here, CEACAM5 is linked to gastric cancer.